IL-17 inhibitors have shown superiority in achieving skin outcomes in psoriatic arthritis compared with TNF inhibitors [17, 18], and ASAS-EULAR recommends that IL-17 inhibitors may be preferred in patients with significant psoriasis [3]. The gene discussed is IL17A; the disease is psoriasis.